AEON Biopharma, Inc.

AEON NYSE CIK: 0001837607

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 5 PARK PLAZA, IRVINE, CA, 92614
Mailing Address 5 PARK PLAZA, IRVINE, CA, 92614
Phone (949) 354-6499
Fiscal Year End 1231
EIN 853940478

Financial Overview

FY2025

$60.59M
Total Liabilities
$3.01M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 3, 2026 View on SEC
3 Initial insider ownership report April 3, 2026 View on SEC
8-K Current report of material events April 3, 2026 View on SEC
10-K Annual financial report March 30, 2026 View on SEC
8-K Current report of material events March 30, 2026 View on SEC
4 Insider stock transaction report March 11, 2026 View on SEC
8-K Current report of material events March 9, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report March 5, 2026 View on SEC
4 Insider stock transaction report February 19, 2026 View on SEC

Annual Reports

10-K March 30, 2026
  • Focused development of ABP-450 for the $3.3 billion U.S. medical botulinum toxin market.
  • Strategic pivot to prioritize cervical dystonia trials over migraine research to conserve capital.
View Analysis

Material Events

8-K Financial Distress April 3, 2026
High Impact
  • Clinical-stage development of ABP-450 continues without operational disruption.
  • Company maintains active clinical trials despite exchange compliance challenges.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.